Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
24 hedge funds and large institutions have $8.68M invested in Interpace Biosciences, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
8% less funds holding
Funds holding: 26 → 24 (-2)
23% less capital invested
Capital invested by funds: $11.2M → $8.68M (-$2.54M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$268K |
| 2 |
LCM
Leonard Capital Management
Vero Beach,
Florida
|
+$126K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$9.16K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.89K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$654 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$254K |
| 2 |
RA
Royce & Associates
New York
|
-$117K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$51K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$48.4K |
| 5 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$32.2K |
IDXG Hedge Fund Activity: Q1 2015 in Review
24 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2015, worth a combined $8.68M — down 23% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IDXG and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Heartland Advisors, adding an estimated $268K. The largest seller was Ancora Advisors, exiting entirely with an estimated $254K sold.
- 24 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2015, down from 26 in Q4 2014.
- Funds reported $8.68M of Interpace Biosciences, Inc. Common Stock stock for Q1 2015, down 23% quarter-over-quarter.
- 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2015 and 4 closed out, a net change of -2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2015 was Heartland Advisors, an estimated $268K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2015 was Ancora Advisors, an estimated $254K sold.
Based on aggregated 13F filings for Q1 2015.